

The Role of Apelin gene polymorphism in obesity

A thesis submitted for the partial fulfillment of Master Degree in
Pharmaceutical Sciences (Biochemistry)

Presented by

Mostafa Ahmed Aboouf ALi

Demonstrator of Biochemistry, Faculty of Pharmacy, Ain Shams University
B. Ph. Sci., Ain Shams University, 2009

Under Supervision of

*Prof. Dr. Hala Osman
EL-Mesallamy*

Professor of Biochemistry
Head of Biochemistry Department
Faculty of Pharmacy
Ain Shams University

*Prof. Dr. Ashraf Ismail
Amin*

Professor of Clinical Pathology
Head of the General Organization of the
Teaching Hospitals and Institutes
Cairo University

Dr. Nadia Hamdy El-Hefny

Associate Professor of Biochemistry
Faculty of Pharmacy
Ain Shams University

**Biochemistry Department
Faculty of Pharmacy
Ain Shams University
2015**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"وَعَلَّمَ آدَمَ الْأَسْمَاءَ كُلَّهَا ثُمَّ عَرَضَهُمْ عَلَى الْمَلَائِكَةِ فَقَالَ

أَنْبِئُونِي بِأَسْمَاءِ هَؤُلَاءِ إِنْ كُنْتُمْ صَادِقِينَ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ *

الْحَكِيمُ"

صدق الله العظيم

سورة البقرة (31 و 32)

Acknowledgment

Acknowledgement

First of all, I do thank **Allah** for leading me all the way to accomplish this work. His guidance and enlightening my way were the ignition behind my persistence. May it be a step towards gaining **Allah**'s mercy and blessings and may **Allah** accept from us the good deeds, and forgive us in shortcomings.

I would like to express my deepest thanks and sincere gratitude to **Dr. Hala Osman El-Mesallamy, Professor of Biochemistry and Vice Dean for Graduate Studies and Research, Faculty of Pharmacy, Ain Shams University**. Her useful comments and remarks have enriched this work greatly till it is presented in the current form. Moreover, her leadership, support and attention to details have set an example I hope to match someday.

I would like to thank **Dr. Ashraf Ismail Amin, Professor of Clinical Pathology and Head of the General Organization of Teaching Hospitals and Institutes, Cairo University**, for his great help, support and allowing the access to National Institute for Diabetes and Endocrinology from where samples were withdrawn.

I would also like to express my gratefulness and appreciation for **Dr. Nadia Hamdy El-Hefny, Associate Professor of Biochemistry and acting as head of Biochemistry Department, Faculty of Pharmacy, Ain Shams University**, for her commitment during the work time, engagement through the learning process of this master thesis.

Last but not least, I extend my most sincere and heartfelt thanks to my **whole family**. I would like to thank namely **my mother, father, brother, sister** and my **mirror image** for their endless love, continuous support, care and patience throughout the work period and my whole life. Thank you dear Lord for having them; without them I am really nothing.

List of Contents

Subjects	Page
LIST OF ABBREVIATIONS.....	I
LIST OF TABLES.....	Iii
LIST OF FIGURES.....	Vi
1. INTRODUCTION AND AIM OF THE WORK.....	1
2. LITERATURE REVIEW.....	4
2.1. Obesity prevalence.....	4
2.2. Health risks of obesity.....	6
2.3. Definition and measurement of obesity.....	8
2.4. Etiology of obesity.....	11
2.5. Obesity and genetics.....	12
2.6. Adipose tissue	14
2.7. Adipogenesis and angiogenesis.....	20
2.8. Obesity and Insulin resistance	22
2.9. Metabolic syndrome.....	26
2.10. Apelin.....	28
2.10.1. Apelin and angiogenesis.....	31
2.10.2. Apelin gene regulation.....	32
2.10.3. Apelin action on insulin responsive tissues	33
2.10.4. Effect of apelin on pancreas	35
2.10.5. Central effect of apelin on energy metabolism	37
3. SUBJECTS AND METHODS.....	38
3.1. Subjects.....	38
3.2. Methods.....	44
3.3. Statistical analysis.....	68
4. RESULTS.....	69
5. DISCUSSION.....	101
6. SUMMARY AND CONCLUSIONS.....	114
7. RECOMMENDATIONS.....	117

List of Contents

8. REFERENCES	118
ARABIC SUMMARY.....	3-1

List of Abbreviations

List of Abbreviations

<u>Abbreviation</u>	<u>Definition</u>
ACE2	Angiotensin converting enzyme 2
Akt	Protein kinase B
ALT	Alanine aminotransferase
AMPK	Adenosine Mono Phosphate activated protein kinase
APLN	Apelin gene
AST	Aspartate aminotransferase
BAT	Brown adipose tissue
BMI	Body mass index
CAD	Coronary artery diseases
CNS	Central nervous system
CV	Cardiovascular
CVD	Cardiovascular diseases
DM	Diabetes mellitus
ECs	Endothelial cells
ELISA	Enzyme linked immunosorbent assay
eNOS	Endothelial nitric oxide synthase
FAO	Fatty acid oxidation
FPG	Fasting plasma glucose
FSI	Fasting serum insulin
GWAS	Genome wide association studies
HDL-C	High density lipoprotein cholesterol
HOMA-IR	Homeostasis model assessment for insulin resistance
HSL	Hormone sensitive lipase
HWE	Hardy-Weinberg equilibrium
IR	Insulin resistance
Interleukin-6	IL-6

List of Abbreviations

LDL-C	Low density lipoprotein cholesterol
LFT	Liver function tests
MAPK	mitogen-activated and ERK kinase
MCP-1	Monocyte chemoattractant protein 1
MetS	Metabolic syndrome
NIDE	National Institute of Diabetes and Endocrinology
PAI-1	Plasminogen activator inhibitor 1
PCR	Polymerase chain reaction
QUICKI	Quantitative insulin sensitivity check index
SAT	Subcutaneous adipose tissue
SNP	Single nucleotide polymorphism
T2DM	Type 2 diabetes mellitus
TAG	Triacylglycerols
TC	Total cholesterol
TNF-α	Tumor necrosis factor alpha
UCP	Uncoupling protein
VAT	Visceral adipose tissue
VEGF	Vascular endothelial growth factor
VLDL	Very low density lipoprotein
WAT	White adipose tissue
WC	Waist circumference
WHO	World health organization
WHR	Waist to hip ratio

List of Tables

List of Tables

Table No.	Title	Page
1	Increased risk of certain diseases in people with a raised BMI...	7
2	The practical methods used in clinical practice to assess obesity.	9
3	Contributing Factors to the obesity Epidemic.....	11
4	Latest criteria defined by the International Diabetes Federation (IDF) for clinical diagnosis of the metabolic syndrome.....	27
5	Clinical and anthropometric data of the studied groups.....	69
6	Fasting plasma glucose and IR parameters of the studied groups.....	70
7	Lipids profile and liver function tests of the study groups.....	71
8	Allelic frequencies in the sample population	72
9	Allelic frequencies in the obese and non-obese groups.....	73
10	Allelic frequencies in the T2DM and non-diabetic groups	73
11	The genotype frequencies of <i>APLN</i> rs3115757 gene polymorphism in the obese and non-obese groups.....	74
12	The genotype frequencies of <i>APLN</i> rs3115757 gene polymorphism in non-obese, obese and morbidly obese groups..	75
13	The genotype frequencies of <i>APLN</i> rs3115757 gene polymorphism in the T2DM and non-diabetic groups.....	76
14	The HWE test for the population sample.....	78
15	The HWE test for obese women.....	79

List of Tables

Table No.	Title	Page
16	The HWE test for non-obese women.....	79
17	The HWE test for T2DM women.....	80
18	The HWE test for non-diabetic women.....	80
19	The differences among genotypes of <i>APLN</i> rs3115757 regarding anthropometric measures across the whole studied population.....	82
20	The differences between <i>GG</i> and <i>CC+CG</i> genotypes of <i>APLN</i> rs3115757 regarding anthropometric measures among the whole population.....	85
21	The differences among genotypes of <i>APLN</i> rs3115757 regarding IR parameters across the whole studied population...	87
22	The differences between <i>CC</i> and <i>CG+GG</i> genotypes of <i>APLN</i> rs3115757 regarding IR parameters across the whole studied population.....	89
23	The differences among genotypes of <i>APLN</i> rs3115757 regarding lipids profile, ALT and AST across the whole studied population.....	91
24	Association of <i>APLN</i> rs3115757 gene polymorphism and study groups.....	92
25	Association of <i>APLN</i> rs3115757 gene polymorphism and obesity defined as BMI into obese and non-obese groups.....	93
26	Association of <i>APLN</i> rs3115757 gene polymorphism and obesity defined as BMI into non-obese, obese and morbidly obese groups.....	93
27	Association of <i>APLN</i> rs3115757 genotypes <i>GG</i> vs <i>CC+CG</i> and obesity defined as BMI into non-obese, obese and morbidly obese groups.....	94
28	Odds Ratio of <i>GG</i> vs <i>CC+CG</i> genotypes of <i>APLN</i> rs3115757 regarding morbid obesity.....	95
29	Odds Ratio of <i>GG</i> vs <i>CC+CG</i> genotypes of <i>APLN</i> rs3115757 regarding morbid obesity after adjustment for age and FSI.....	95

List of Tables

Table No.	Title	Page
30	Association of <i>APLN</i> rs3115757 gene polymorphism and T2DM.....	96
31	Odds Ratio of <i>GG</i> vs <i>CC+CG</i> genotypes of <i>APLN</i> rs3115757 regarding FSI.....	97
32	Association of <i>APLN</i> rs3115757 gene polymorphism and hypertension.....	97
33	Cochran-Armitage trend test for case-control samples of the <i>APLN</i> rs311575 under the recessive model.....	98
34	Association of <i>APLN</i> rs3115757 gene polymorphism G/C alleles and obesity defined by BMI, into non-obese and obese groups.....	99
35	Association of <i>APLN</i> rs3115757 gene polymorphism G/C alleles and obesity defined by BMI, into non-obese, obese and morbidly obese groups.....	99
36	Odds Ratio of <i>G</i> vs <i>C</i> alleles of <i>APLN</i> rs3115757 regarding morbid obesity.....	100
37	Individual data of control non-obese group.....	142
38	Individual data of obese diabetic group.....	144
39	Individual data of obese non diabetic group.....	149

List of Figures